drugset
Drugs / SUDOCETAXEL ZENDUSORTIDE
last change Jan 2026 re-read 3 minutes ago

SUDOCETAXEL ZENDUSORTIDE

also known as Sudocetaxel zendusortida · TH1902 · Th19p01-docetaxel

Peptide

Developed for
cutaneous melanoma · endometrial cancer · hormone receptor-positive breast cancer · malignant epithelial tumor of ovary · prostate cancer · small cell lung carcinoma · thyroid cancer · triple-negative breast carcinoma
Investigated by
Altasciences Company Inc. · Innovaderm Research Inc. · PPD Development, LP · Syneos Health · Theratechnologies · Windtree Therapeutics

Trials 1

today NCT04706962 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04706962 Mar 2021 → Dec 2025 overdue cutaneous melanoma, endometrial cancer, hormone receptor-positive breast cancer, malignant epithelial tumor of ovary +4 Theratechnologies Active not recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as SUDOCETAXEL ZENDUSORTIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL5095153 ↗
Known as Sudocetaxel zendusortida ChEMBL registry synonym — accepted as the source's own label CHEMBL5095153 ↗
Known as TH1902 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04706962 ↗
Known as Th19p01-docetaxel ChEMBL registry synonym — accepted as the source's own label CHEMBL5095153 ↗
Modality Peptide “TH1902 peptide-drug conjugate” NCT04706962 ↗